Cargando…

NASH, Metabolic Syndrome, and Diabetes: How Sugar and Fat Increase the Risk of Developing Advanced Liver Disease

Detalles Bibliográficos
Autores principales:	Manka, Paul, Syn, Wing-Kin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236040/ https://www.ncbi.nlm.nih.gov/pubmed/32979160 http://dx.doi.org/10.1007/s10620-020-06620-9

Ejemplares similares

Non-Invasive Risk Stratification in NAFLD/NASH Patients for Screening EGD
por: Romano, John, et al.
Publicado: (2022)

A Review of the Epidemiology, Pathophysiology, and Efficacy of Anti-diabetic Drugs Used in the Treatment of Nonalcoholic Fatty Liver Disease
por: Manka, Paul P., et al.
Publicado: (2021)

Role of liver progenitors in acute liver injury
por: Best, Jan, et al.
Publicado: (2013)

NASH‐related cirrhosis: An occult liver disease burden
por: Arrese, Marco, et al.
Publicado: (2017)

Modeling NASH and NASH-Induced Hepatocellular Carcinoma: Faster and Better
por: Hirsova, Petra
Publicado: (2021)

Editorial: Noninvasive Fibrosis Biomarkers in Patients With NASH With Diabetes
por: Fan, Weiguo, et al.
Publicado: (2021)

Alarming increase of NASH as cause of liver cancer
por: Craciun, Ana, et al.
Publicado: (2022)

Is Assessing the Presence of NASH by Liver Histology or Surrogate Markers Always Advisable?
por: Tarantino, Giovanni
Publicado: (2013)

NASH: Connecting the dots with patients in mind
por: Cryer, Donna R.
Publicado: (2020)

Something to mTORC About in NASH
por: Finck, Brian N.
Publicado: (2022)

Increased Expression of RUNX1 in Liver Correlates with NASH Activity Score in Patients with Non-Alcoholic Steatohepatitis (NASH)
por: Kaur, Savneet, et al.
Publicado: (2019)

Transmitting Diet‐Related Microbial Benefit through Fecal Microbiota Transplant in NASH: Can Microbiota Cut Through the Fat?
por: Acharya, Chathur, et al.
Publicado: (2020)

Role of Metabolism in Hepatic Stellate Cell Activation and Fibrogenesis
por: Hou, Wei, et al.
Publicado: (2018)

From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
por: Gastaldelli, Amalia, et al.
Publicado: (2019)

Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis: Molecular and Multicellular Control of Evolving Diseased States
por: Eeckhoute, Jérôme
Publicado: (2022)

Saturated Fat Is More Metabolically Harmful for the Human Liver Than Unsaturated Fat or Simple Sugars
por: Luukkonen, Panu K., et al.
Publicado: (2018)

From the origin of NASH to the future of metabolic fatty liver disease
por: Geier, Andreas, et al.
Publicado: (2021)

Letter from Dr. Nash
por: Hart, James A.
Publicado: (1875)

Addressing the sugar, salt, and fat issue the science of food way
por: Rao, Pingfan, et al.
Publicado: (2018)

The Presence of Periodontitis Exacerbates Non-Alcoholic Fatty Liver Disease via Sphingolipid Metabolism-Associated Insulin Resistance and Hepatic Inflammation in Mice with Metabolic Syndrome
por: Lu, Zhongyang, et al.
Publicado: (2023)

Targeting bile acids and lipotoxicity for NASH treatment
por: Chiang, John Y. L.
Publicado: (2017)

Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC
por: Kim, Hyunmi, et al.
Publicado: (2021)

MerTK, a risk factor for NASH fibrosis
por: Wang, Xiaobo, et al.
Publicado: (2020)

NASH and Systemic Complications: From Basic to Clinical Research
por: Baumgartner, Sabine, et al.
Publicado: (2021)

Sugar-Sweetened Beverages and Artificially Sweetened Beverages Consumption and the Risk of Nonalcoholic Fatty Liver (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
por: Tseng, Tung-Sung, et al.
Publicado: (2023)

Sugar and fat – that's where it's at: metabolic changes in tumors
por: Young, Christian D, et al.
Publicado: (2008)

Sugar, Salt, Fat, and Chronic Disease Epidemic in India: Is There Need for Policy Interventions?
por: Dasgupta, Rajib, et al.
Publicado: (2015)

Characterizing the Heterogeneity of Liver Cell Populations Under a NASH-Related Hepatotoxicant Using Single-Nuclei RNA Sequencing
por: Rodrigues, Pedro M., et al.
Publicado: (2020)

Innovative Molecular Target and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 2.0
por: Vairetti, Mariapia, et al.
Publicado: (2022)

Low Levels of Blood Lipids Are Associated with Etiology and Lethal Outcome in Acute Liver Failure
por: Manka, Paul, et al.
Publicado: (2014)

Transcriptomics Identify Thrombospondin‐2 as a Biomarker for NASH and Advanced Liver Fibrosis
por: Kozumi, Kazuhiro, et al.
Publicado: (2021)

Fat, Muscle, and Bone Interactions in Obesity and the Metabolic Syndrome
por: Armamento-Villareal, Reina, et al.
Publicado: (2014)

Markers of Tissue Repair and Cellular Aging Are Increased in the Liver Tissue of Patients With HIV Infection Regardless of Presence of HCV Coinfection
por: Naggie, Susanna, et al.
Publicado: (2018)

Liver Protein Expression in NASH Mice on a High-Fat Diet: Response to Multi-Mineral Intervention
por: Varani, James, et al.
Publicado: (2022)

Treatment potential of LPCN 1144 on liver health and metabolic regulation in a non-genomic, high fat diet induced NASH rabbit model
por: Comeglio, P., et al.
Publicado: (2021)

Sugar-induced dysregulation of purine metabolism impacts lifespan
por: Lennicke, Claudia, et al.
Publicado: (2020)

Special Issue “Sugar Transport, Metabolism and Signaling in Plants”
por: Sakr, Soulaiman
Publicado: (2023)

NRF2 Induction for NASH Treatment: A New Hope Rises
por: Rojo de la Vega, Montserrat, et al.
Publicado: (2018)

Osr1 Is a Critical Regulator of Macrophage Polarization in NASH Progression
por: Lee, Jin, et al.
Publicado: (2023)

Sugar or Fat?—Metabolic Requirements for Immunity to Viral Infections
por: Shehata, Hesham M., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_aectilqpv1qlboqcnjcg350m4p